| ¿µ¹® | cancer chemotherapy | ÇÑ±Û | Ç×¾ÏÈÇпä¹ý |
|---|---|---|---|
| ¼³¸í | ÈÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀÎ Ç×¾ÏÁ¦´Â Á¤»óÀûÀÎ ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀÎ È¿°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀÇ Æ¯ÀÌÇÑ Æ¯¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇÏ´Â ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í ÀÖ´Â DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒȰüÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀÎ ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒȺҷ®ÀÌ À߿´Ù). |
||
| ¿µ¹® | chemotherapy | ÇÑ±Û | ÈÇпä¹ý |
|---|---|---|---|
| ¼³¸í | ÈÇÐÀû ¹°Áú·Î º´À» Ä¡·áÇÏ´Â °ÍÀ» ¸»ÇÑ´Ù. ¿ö³« ¼¼±Õ°¨¿°À» Ä¡·áÇÏ´Â ¹æ¹ýÀ¸·Î ÁÖ·Î »ç¿ëµÇ¾úÀ¸³ª ¿äÁöÀ½¿¡ ¿Í¼´Â ¾ÏÀ» Ä¡·áÇÏ´Â ¹æ¹ýÀ¸·Î ´õ ¸¹ÀÌ ¾²À̰í ÀÖ´Ù. |
||
| CT | calcitonin; calf testis; cardiac tamponade; cardiothoracic [ratio]; carotid tracing; carpal tunnel; ... |
|---|---|
| SCC | self-care center; sequential combination chemotherapy; services for crippled children; short-course ... |
| Tc cell | cytotoxic T cell |
| ACS | acrocallosal syndrome; acrocephalosyndactyly; acute chest syndrome; acute confusional state; Alcon C... |
| CA | anterior commissure [Lat. commissura anterior]; calcium antagonist; California [rabbit]; cancer; Can... |
| CHOP | Chemotherapy |
|---|---|
| CHT | Chemotherapy |
| CT | Chemotherapy |
| HAIC | Hepatic arterial infusion chemotherapy |
| HDC | High dose chemotherapy |
| antireticular cytotoxic serum | An antiserum specific for cells of the reticuloendothelial system. (05 Mar 2000) |
|---|---|
| cytotoxic | <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration. (16 Dec 1997) |
| cytotoxic cell | Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells. Synonym: cytotoxic cell. (05 Mar 2000) |
| cytotoxic drugs | <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells. See: chemotherapy. (13 Nov 1997) |
| cytotoxic reaction | An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement. (05 Mar 2000) |
| cytotoxic T-cell | <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens). (18 Nov 1997) |
| cytotoxic t-lymphocyte | A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene: See: Ganciclovir. (09 Oct 1997) |
| cytotoxic T lymphocyte-specific serine protease | <enzyme> Structural sequence given in first source Registry number: EC 3.4.21.- Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II (26 Jun 1999) |
| T cytotoxic cells | Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors. (12 Dec 1998) |
| T-lymphocytes, cytotoxic | Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity. (12 Dec 1998) |
| adjuvant chemotherapy | <oncology, pharmacology> Chemotherapy treatment that is given as an add-on to their primary cancer treatment, as in surgery or radiation therapy. (16 Dec 1997) |
| remission induction chemotherapy | The initial chemotherapy a patient receives to bring about a remission. (12 Dec 1998) |
| chemotherapy | <pharmacology, oncology> The treatment of disease by means of chemicals that have a specific toxic effect upon the disease producing microorganisms (antibiotics) or that selectively destroy cancerous tissue (anticancer therapy). (12 May 1997) |
| chemotherapy, adjuvant | Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment. (12 Dec 1998) |
| chemotherapy drug sensitivity test | <investigation> A test to assess a cancerous tissue's response and vulnerability to chemotherapy drugs. This test can help predict a patients response to treatment and suggest which drugs may be useful. (16 Dec 1997) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|